Search research articles
Contact Us
Filters
Showing results (41-50 of 61) with videos related to
Page
of 7
Sort By:
Journal of the National Cancer Institute
|
June 8, 2018
Adjuvant Anti-HER2 Therapy, Treatment-Related Amenorrhea, and Survival in Premenopausal HER2-Positive Early Breast Cancer Patients
Matteo Lambertini, Christine Campbell, José Bines, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
January 7, 2015
PIK3CA mutations are associated with decreased benefit to neoadjuvant human epidermal growth factor receptor 2-targeted therapies in breast cancer
Ian J Majewski, Paolo Nuciforo, Lorenza Mittempergher, et al.
European Journal of Cancer (Oxford, England : 1990)
|
July 9, 2019
The 41-gene classifier TRAR predicts response of HER2 positive breast cancer patients in the NeoALTTO study
Serena Di Cosimo, Tiziana Triulzi, Sara Pizzamiglio, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
October 18, 2019
Lucitanib for the Treatment of HR<sup>+</sup>/HER2<sup>-</sup> Metastatic Breast Cancer: Results from the Multicohort Phase II FINESSE Study
Rina Hui, Alex Pearson, Javier Cortes, et al.
Journal of the National Cancer Institute
|
May 5, 2022
Impact of Age on Clinical Outcomes and Efficacy of Adjuvant Dual Anti-HER2 Targeted Therapy
Matteo Lambertini, Shona Fielding, Sibylle Loibl, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
September 28, 2011
Estrogen receptor (ESR1) mRNA expression and benefit from tamoxifen in the treatment and prevention of estrogen receptor-positive breast cancer
Chungyeul Kim, Gong Tang, Katherine L Pogue-Geile, et al.
JAMA Oncology
|
September 30, 2016
RNA Sequencing to Predict Response to Neoadjuvant Anti-HER2 Therapy: A Secondary Analysis of the NeoALTTO Randomized Clinical Trial
Debora Fumagalli, David Venet, Michail Ignatiadis, et al.
Breast Cancer Research and Treatment
|
December 28, 2017
Cardiac biomarkers for early detection and prediction of trastuzumab and/or lapatinib-induced cardiotoxicity in patients with HER2-positive early-stage breast cancer: a NeoALTTO sub-study (BIG 1-06)
Noam Ponde, Ian Bradbury, Matteo Lambertini, et al.
European Journal of Cancer (Oxford, England : 1990)
|
August 5, 2019
Survival outcomes of the NeoALTTO study (BIG 1-06): updated results of a randomised multicenter phase III neoadjuvant clinical trial in patients with HER2-positive primary breast cancer
Jens Huober, Eileen Holmes, José Baselga, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
May 14, 2016
Loss of ARID1A Activates ANXA1, which Serves as a Predictive Biomarker for Trastuzumab Resistance
Katrien Berns, Amir Sonnenblick, Annemiek Gennissen, et al.
Page
of 7
Search research articles
Search
Showing results (41-50 of 61) with videos related to
Sort By:
Page
of 7
Journal of the National Cancer Institute
|
June 8, 2018
Adjuvant Anti-HER2 Therapy, Treatment-Related Amenorrhea, and Survival in Premenopausal HER2-Positive Early Breast Cancer Patients
Matteo Lambertini, Christine Campbell, José Bines, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
January 7, 2015
PIK3CA mutations are associated with decreased benefit to neoadjuvant human epidermal growth factor receptor 2-targeted therapies in breast cancer
Ian J Majewski, Paolo Nuciforo, Lorenza Mittempergher, et al.
European Journal of Cancer (Oxford, England : 1990)
|
July 9, 2019
The 41-gene classifier TRAR predicts response of HER2 positive breast cancer patients in the NeoALTTO study
Serena Di Cosimo, Tiziana Triulzi, Sara Pizzamiglio, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
October 18, 2019
Lucitanib for the Treatment of HR<sup>+</sup>/HER2<sup>-</sup> Metastatic Breast Cancer: Results from the Multicohort Phase II FINESSE Study
Rina Hui, Alex Pearson, Javier Cortes, et al.
Journal of the National Cancer Institute
|
May 5, 2022
Impact of Age on Clinical Outcomes and Efficacy of Adjuvant Dual Anti-HER2 Targeted Therapy
Matteo Lambertini, Shona Fielding, Sibylle Loibl, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
September 28, 2011
Estrogen receptor (ESR1) mRNA expression and benefit from tamoxifen in the treatment and prevention of estrogen receptor-positive breast cancer
Chungyeul Kim, Gong Tang, Katherine L Pogue-Geile, et al.
JAMA Oncology
|
September 30, 2016
RNA Sequencing to Predict Response to Neoadjuvant Anti-HER2 Therapy: A Secondary Analysis of the NeoALTTO Randomized Clinical Trial
Debora Fumagalli, David Venet, Michail Ignatiadis, et al.
Breast Cancer Research and Treatment
|
December 28, 2017
Cardiac biomarkers for early detection and prediction of trastuzumab and/or lapatinib-induced cardiotoxicity in patients with HER2-positive early-stage breast cancer: a NeoALTTO sub-study (BIG 1-06)
Noam Ponde, Ian Bradbury, Matteo Lambertini, et al.
European Journal of Cancer (Oxford, England : 1990)
|
August 5, 2019
Survival outcomes of the NeoALTTO study (BIG 1-06): updated results of a randomised multicenter phase III neoadjuvant clinical trial in patients with HER2-positive primary breast cancer
Jens Huober, Eileen Holmes, José Baselga, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
May 14, 2016
Loss of ARID1A Activates ANXA1, which Serves as a Predictive Biomarker for Trastuzumab Resistance
Katrien Berns, Amir Sonnenblick, Annemiek Gennissen, et al.
Page
of 7